Long‐term outcomes after paclitaxel‐coated balloon angioplasty of femoropopliteal arteries in Asian patients of the IN.PACT Global Study. Issue 7 (16th November 2022)

• Record Type: Journal Article
• Authors: Ko, Young‐Guk; Choi, Donghoon; Rha, Seung‐Woon; Won, Je Hwan; Do, Young‐Soo; Lee, Seung‐Whan; Menk, Jeremiah S.; Kum, Steven
• Is Part Of: Catheterization and cardiovascular interventions. Volume 100:Issue 7(2022)
• Page Start: 1273
• Page End: 1283
• Publication Date: 2022-11-16
• Subjects: Asian -- clinically driven target lesion revascularization -- drug‐coated balloons -- paclitaxel -- peripheral artery disease -- real‐world; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.30441
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Objectives: The long‐term data on the use of drug‐coated balloons (DCBs) for femoropopliteal atherosclerotic lesions in the real‐world setting are limited, even more so for racially and geographically distinct populations. The present analysis reports the 5‐year safety and effectiveness outcomes of a DCB in the Asian subset of the prospective, real‐world IN.PACT Global Study. Methods: The IN.PACT Global Study was a prospective, multicenter, international, single‐arm study designed to assess the long‐term safety and effectiveness of the IN.PACT Admiral DCB in real‐world participants with femoropopliteal artery disease. The present analysis included 114 Asian participants (138 lesions) treated in South Korea and Singapore. Assessments through 5 years included freedom from clinically driven target lesion revascularization, the safety endpoint (a composite of freedom from device‐ and procedure‐related mortality through 30 days; and freedom from major target limb amputation and clinically driven target vessel revascularization within 60 months after the index procedure) and major adverse events. Results: In this prespecified Asian subset, there was a high incidence of diabetes mellitus (54.4%), hypertension (78.1%), coronary artery disease (43.9%), and concomitant below‐the‐knee vascular disease of target leg (39.5%). Mean lesion length was 17.4 ± 12.4 cm; 26.8% were in‐stent restenosis, and more than half of the lesions were totally occluded (51.4%) and calcified (54.3%). The 5‐year Kaplan–Meier estimate of freedom from clinically driven target lesion revascularization was 77.1% (95% confidence interval: 67.0%–84.5%). The safety composite endpoint was 76.0%; the cumulative incidence of all‐cause mortality was 19.9%, and no major target limb amputations were reported through 5 years. Conclusions: This subset analysis of Asian participants from the IN.PACT Global Study demonstrated consistent results with the previously reported data of the IN.PACT Admiral DCB. The data confirm the durable clinical effectiveness and safety profile of the DCB through 5 years for femoropopliteal atherosclerotic disease in this real‐world population.